Print PDF
Axinn's Chad Landmon Speaks with Drug Industry Daily About the Drug Price Competition Act of 2009
June 25, 2009
Drug Industry Daily

Senator Bill Nelson (D-Fla.) has introduced the Drug Price Competition Act of 2009, a bill that could potentially  impact  how generic-drug makers are awarded 180-day exclusivity for their ANDA  products . The bill, introduced on June 25, 2009, would allow a subsequent filer to qualify as a first applicant and trigger  the 180-day exclusivity  period. Chad Landmon, Chair of the FDA  Practice  Group at Axinn, spoke with Drug Industry Daily about the potential  impact of the bill if it becomes law, saying, “Ultimately, I think a bill like this will certainly devalue the exclusivity period while at the same time providing opportunities for certain later filers . ”

The article, titled, “Senate Drug Price Bill May Alter 180-Day Exclusivity Awards,” was published on June 25, 2009. Click here to view a copy of the article.

From Drug Industry Daily, copyright © 2009 by Washington Business Information, Inc. (FDAnews). All rights reserved., (888) 838-5578,  +1 (703) 538-7600.

Additional Documents:

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.